Use of an anti-g-csf or anti-g -csfr antibody or a soluble g- csfr for the treatment or prophylaxis of arthritis
CA 2496485 C · Owner: Wicks, Ian Peter · Inventors: Lawlor, Kathryn Elizabeth; Campbell, Ian Keith; Roberts, Andrew Warwick
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates generally to the use of agents for treating or preventing or otherwise ameliorating the effects of inflammatory conditions such as but not limited to chronic immune-mediated inflammatory diseases such as arthritis. Specifically, the invention relates to the use of an agent which , inhibits the activity of granulocyte-colony stimulating factor (G-CSF) or granulocyte-colony stimulating factor receptor (G-CSFR) for the treatment or prophylaxis of arthritis in a subject, wherein said agent is (i) an antibody raised , against G-CSF or G-CSFR, or (ii) a soluble G-CSFR. The invention also provides the use of a DNA or RNA sense or antisense polynucleotide …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 22, 2003 and granted July 15, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 22, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 22, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.